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g/kg/min) infusion, which did not alter hemodynamics, as
compared with a higher dose (0.015 g/kg/min) infusion, which
reduced BP.
In conclusion, further prospective randomized controlled stud-
ies are warranted to test the efficacy of non-hypotensive low-dose
nesiritide such as 0.005 g/kg/min and the current dose of 0.01
g/kg/min without the bolus of 2 g/kg/min in enhancing renal
function in patients with acute decompensated CHF and renal
dysfunction as well as defining the mechanisms of the renal-
enhancing actions of such a strategy.
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A Biomarker of Myocardial Fibrosis Predicts Long-Term Response to
Cardiac Resynchronization Therapy
To the Editor: Serum concentrations of the carboxy-terminal
propeptide of procollagen type I (PICP), a peptide that is cleaved
from procollagen type I during the synthesis of fibril-forming
collagen type I (CTI), may provide indirect diagnostic information
on both the synthesis of fibril-forming CTI molecules and the
extent of myocardial deposition of CTI fibers (1). We investigated
whether PICP is related to the clinical long-term response to cardiac
resynchronization therapy (CRT) in heart failure (HF) patients.
Thirty-eight consecutive patients were prospectively studied.
All patients received CRT for New York Heart Association
(NYHA) functional class III/IV HF, left ventricular (LV) ejection
fraction (EF) 35%, and QRS 130 ms. Twenty healthy subjects
were included as control subjects.
Patients were evaluated at baseline and at the 1-year follow-up.
Evaluation included NYHA functional class, 6-min walk test,
blinded echocardiographic study with measurement of interven-
tricular and intraventricular dyssynchrony parameters (septal-to-
posterior-wall motion delay [SPWMD] and septal-to-lateral-wall
motion delay [SLWMD]), and obtaining of blood samples. At 1
year, patients were categorized as nonresponders if they died of
HF, were scheduled for heart transplantation, or did not increase
the distance walked in 6 minutes by 10%.
Serum PICP was determined by a sandwich enzyme-linked
immunosorbent assay (ELISA) (inter- and intra-assay variations
were 6.3% and 6.4%, respectively). The minimum analytical
detection limit was 1 g/l. Serum amino-terminal propeptide of
brain natriuretic peptide (NT-proBNP) was measured by ELISA
(inter- and intra-assay coefficients of variation lower than 2%).
Differences between baseline values and between final values in
the two groups of patients were analysed with the Mann-Whitney
U test for SLWMD, interventricular dyssynchrony, and NT-
proBNP and with the Student t test for unpaired data for the rest
of the quantitative variables. Intragroup comparisons between
baseline and final values were analyzed with the Wilcoxon test
(SLWMD, interventricular dyssynchrony, and NT-proBNP) and
with the Student t test for paired data for the rest of quantitative
variables. Categoric variables were analyzed by chi-square test.
Significant variables in univariate analysis were used in logistic
regression analysis to predict the probability of positive response to
CRT. A model was constructed using stepwise variable selection,
verified with the Hosmer-Lemeshow test. Receiver-operating
characteristic (ROC) curves allowed determination of the overall
performance for predicting a positive response to CRT. The results
are expressed as mean  SD.
At 1 year, 26 patients (68%) were considered responders to CRT
(Table 1). At baseline, nonresponders exhibited higher left ventricular
end-diastolic diameter (LVEDD) and lower SLWMD than respond-
ers (p  0.05). Baseline PICP was higher in responders than in
controls (p  0.01) and nonresponders (p  0.05). Baseline NT-
proBNP was higher (p 0.001) in the two groups of patients than in
controls (36  5 pg/ml). Baseline NT-proBNP was increased (p 
0.05) in responders compared with nonresponders.
Whereas EF, LV diameters, and the dyssynchrony parameters
decreased (p  0.05) at 1 year in responders, they remained
unchanged in nonresponders. At 1 year, PICP decreased (p 
0.005) in responders and increased (p  0.005) in nonresponders.
Whereas in responders PICP decreased in 21 patients (81%) and
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Table 1. Effects of CRT in Heart Failure Patients Separated According to the Response
Responders Nonresponders
Baseline 1 yr Baseline 1 yr
Age (yrs) 67  8 69  7
NYHA functional class 3.3  0.5 2.0  0.6† 3.1  0.7 2.9  0.8
6-min walk test (m) 327  129 437  200† 367  191 360  173
Ischemic etiology (%) 46 75
Medical treatment (%)
RAS-I 100 100 100 100
Beta-blockers 50 58 58 58
Spironolactone 20 16 25 25
LVEDD (mm) 66.2  9.5 61.5  7.7† 73.9  8.8* 71.3  10.4
LVESD (mm) 56.1  10.1 49.1  10.4† 61.4  9.6 58.1  12.6
EF (%) 25.8  6.1 37.1  10.0† 25.4  5.8 26.8  6.6
Dyssynchrony (ms)
SPWMD 204.8  79.5 63.3  43.4† 207.2  80.1 173.3  70.5
SLWMD 141.6  82.0 39.1  41.7† 89.4  46.2* 60.5  32.7
Interventricular 47.2  23.7 25.9  25.5† 49.4  34.7 29.5  19.4
Serum PCIP (g/l) 101  34 82  21‡ 57  18* 91  34†
Serum NT-proBNP (pg/ml) 2,926  1,326 1,354  1,132 1,900  1,793* 1,946  1,568
*p 0.05 baseline values responders vs. nonresponders; †p 0.05 baseline vs. 1 year in responders; ‡p 0.005 baseline vs. 1 year
in responders and nonresponders.
EF  ejection fraction; LVEDD  left ventricular end-diastolic diameter; LVESD  left ventricular end-systolic diameter;
NT-proBNP  amino-terminal propeptide of brain natriuretic peptide; PICP  carboxy-terminal propeptide of procollagen
type I; RAS-I  renin-angiotensin system inhibition; SLWMD  septal-to-lateral-wall motion delay; SPWMD 
septal-to-posterior-wall motion delay.
Figure 1. Receiver-operating characteristic curves for cardiac (left ventricular end-diastolic diameter [LVEDD] and septal-to-lateral-wall motion
delay [SLWMD]) (left) and biochemical (carboxy-terminal propeptide of procollagen type I [PICP] and amino-terminal propeptide of brain
natriuretic peptide [NT-proBNP]) (right) parameters for determining a positive response to CRT. AUC  area under curve; CI  confidence
interval.
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increased in 5 patients (19%), in nonresponders PICP decreased in
1 patient (8%) and increased in 11 patients (92%); these differences
were significant (p  0.05).
The NT-proBNP level tended to decrease in responders at 1
year, although the difference was not significant; NT-proBNP was
unchanged in nonresponders.
Significant associations were observed between positive re-
sponse to CRT and high baseline values of PICP (73 g/l) (chi
square  16.29; p  0.001) and low baseline values of LVEDD
(67.5 mm) (chi square  5.37; p  0.05). The only independent
predictor of a positive response to CRT was PICP (odds ratio 13.9,
95% confidence interval 7 to 97; p  0.001). The accuracy of the
model was confirmed by the nonsignificant Hosmer-Lemeshow
goodness-of-fit-test (p  0.796)
As shown in Figure 1, PICP exhibited the larger area under the
ROC curve. In addition, only the area under the ROC curve for
PICP and LVEDD was higher (p  0.001 and p  0.05,
respectively) than 0.50. The cutoff value of PICP showed better
sensitivity and specificity than the others parameters analyzed. The
odds ratio of presenting a favorable response to CRT was higher
for patients with PICP 73 g/l than for patients with NT-
proBNP815 pg/ml, LVEDD67.5 mm, or SLWMD95 ms.
These findings can be summarized as follows: 1) an association
exists between abnormally high baseline serum PICP and a
positive long-term response to CRT in HF patients; 2) whereas
the beneficial effects of CRT are associated with its ability to
normalize serum PICP, the lack of benefit is associated with
enhancement of serum PICP; and 3) serum PICP is more accurate
than some echocardiographic parameters and NT-proBNP in the
prediction of a positive long-term response to CRT.
Previous studies have shown that circulating PICP detected in HF
patients is essentially of cardiac origin and that serum PICP is a
reliable index of the amount of CTI present within the myocardium
(2,3). Therefore, the present study suggests that ventricular dyssyn-
chrony may induce excessive cardiac synthesis and deposition of CTI
fibrils and that limitation of these alterations may be one of the
mechanisms contributing to the positive effect of CRT. Our results
would suggest also that stimulation of CTI synthesis and deposition
may account for a negative response to CRT.Whatever are the factors
determining these two patterns of response, it appears that long-term
responses to this therapy are linked to its ability to interfere with
myocardial fibrosis. Additional studies aimed to evaluate histologically
measured myocardial collagen deposition in CRT patients are neces-
sary to prove these hypotheses.
Some findings reported here suggest that PICP adds predictive
value to other indices of response to CRT. First, serum PICP was the
only independent predictor of a positive response to CRT. Second,
serum PICP was a highly sensitive and specific parameter in the
identification of a positive long-term response to CRT. Third,
patients with serum levels of PICP 73 g/l had an almost 28-fold
higher probability of presenting a positive response to CRT, showing
the highest performance for predicting a positive response to CRT.
In conclusion, the determination of serum PICP may be useful
for predicting the response to CRT. However, we are aware that
this was a study involving a relatively small number of patients with
heterogeneous etiologies. Albeit preliminary, these findings set the
stage for large-scale studies to definitively validate this approach.
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Paired Ventricular Stimulation: An Approach for Hemodynamic Stabilization
During Ventricular Tachycardia
To the Editor: Despite great efforts and success in terminating
ventricular tachycardia (VT) by methods like cardioversion and
overdrive stimulation, there are situations in which VTs are
ongoing (incessant VT) despite aggressive therapy. We assessed a
stimulation technique for hemodynamic stabilization during VT.
A ventricular extrasystole occurring shortly after the effective
ventricular refractory period generates a postextrasystolic pause and
leads to an augmentation of the arterial pressure wave initiated by
the next spontaneous beat. This phenomenon was originally
described by Langendorff (1). We speculated that single premature
ventricular beats during an ongoing VT might have a similar effect.
The premature beats would be introduced with coupling intervals
longer than the ventricular refractory period but shorter than the
VT cycle length. The subsequent postextrasystolic pause should
prolong the diastolic filling time, resulting in an augmented
pressure wave initiated by the next spontaneous VT beat. Postex-
trasystolic potentiation of contractile force should contribute to
hemodynamic stabilization during VT.
In 22 patients (70  8 years, ejection fraction 38  14%) with
a history of spontaneous VT (n  21) or ventricular fibrillation
(VF) (n  1) and inducible sustained VT during an electrophys-
iological study (n  16) or ablation procedure (n  6), paired
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